Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new treatments to be investigated both in the early stage of the disease and in the advanced setting. In particular, expectations are now high that immunotherapy will have a leading role in the next years. However, caution is required as results from phase II studies in MPM were often not replicated in larger, randomized, phase III trials. In this review, we describe the most promising emerging therapies for the treatment of MPM, discussing the biological rationale underlying their development as well as the issues surrounding clinical trial design and proper selection of patients for every treatment.

Additional Metadata
Keywords anti-angiogenic, checkpoint inhibitors, dendritic cell therapy, immunotherapy, Malignant mesothelioma, mesothelin, targeted therapy, tumor-treating fields
Persistent URL dx.doi.org/10.3389/fonc.2020.00343, hdl.handle.net/1765/126036
Journal Frontiers in Oncology
Citation
Cantini, L. (Luca), Hassan, R. (Raffit), Sterman, D.H. (Daniel H.), & Aerts, J.G.J.V. (2020). Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. Frontiers in Oncology (Vol. 10). doi:10.3389/fonc.2020.00343